COVID-19 Pathophysiology
Cross-source consensus on COVID-19 Pathophysiology from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Highlighted claims
- SARS-CoV-2 binds ACE2 receptors distributed broadly across the vascular endothelium of many organs, enabling multi-organ spread. — COVID-19: Treatment, Pathophysiology, and Clinical Management — Clinical Q&A
- COVID-19 is best understood as a multi-organ vascular disease rather than primarily a respiratory illness. — COVID-19: Treatment, Pathophysiology, and Clinical Management — Clinical Q&A
- Persistent post-COVID symptoms in PCR-negative patients confirm that the downstream pathophysiology is independent of active viral replication. — COVID-19: Treatment, Pathophysiology, and Clinical Management — Clinical Q&A
- Pulmonary microclots in COVID-19 are unusually rich in von Willebrand factor and platelets, differing from the typical composition of a peripheral venous embolus and suggesting in-situ formation. — COVID-19: Treatment, Pathophysiology, and Clinical Management — Clinical Q&A
- A post-infectious hyperinflammatory syndrome mimicking Kawasaki disease has been observed in children after COVID-19, driven by residual antibodies following viral clearance. — COVID-19: Treatment, Pathophysiology, and Clinical Management — Clinical Q&A